IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11058903 B1

PDFFull Text
Date of Patent:
Jul. 13, 2021

Filed:

Dec. 21, 2018

Methods for identifying and treating cachexia or pre-cachexia using an inhibitor of rage

Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

David K. Thomas, Cambridge, MA (US);

Todd R. Golub, Cambridge, MA (US);

Assignees:

THE BROAD INSTITUTE, INC., Cambridge, MA (US);

DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);

Attorneys:

Greenberg Traurig, LLP

Melissa Hunter-Ensor

Leslie Serunian

Primary Examiner:

Zachary C Howard

Int. Cl.
CPC ...
A61P 21/06 (2006.01); A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 38/04 (2006.01); C07K 16/28 (2006.01); A61K 31/05 (2006.01); A61K 31/164 (2006.01); A61K 31/454 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/7068 (2006.01); A61K 38/00 (2006.01); C07K 14/705 (2006.01); C07K 7/08 (2006.01); G01N 33/53 (2006.01); A61P 3/00 (2006.01); G01N 33/68 (2006.01); G01N 33/50 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61P 21/06 (2018.01); A61K 31/05 (2013.01); A61K 31/164 (2013.01); A61K 31/454 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/7068 (2013.01); A61K 38/00 (2013.01); A61K 38/04 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); C07K 16/2803 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61P 3/00 (2018.01); G01N 33/5061 (2013.01); G01N 33/5067 (2013.01); G01N 33/53 (2013.01); G01N 33/5308 (2013.01); G01N 33/6893 (2013.01); G01N 2800/04 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01);
Abstract

The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.

Find Patent Forward Citations

Loading…